Abatacept in Immune Checkpoint Inhibitor Myocarditis Trial
Phase 3
390
about 4.8 years
18+
29 sites in CA, DC, FL +18
What this study is about
This trial is testing whether abatacept, as compared to placebo, reduces major adverse cardiac events (MACE) in adults hospitalized with myocarditis caused by immune checkpoint inhibitors. MACE includes cardiovascular death, sudden cardiac arrest, cardiogenic shock, significant arrhythmias, or incident heart failure.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Abatacept plus
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
abatacept
injection, intravenous
Primary: Major adverse cardiac events
Secondary: Other immune-related adverse events between the two groups
Oncology